Orfiril (Sodium Valproate)

Sodium valproate increases the activity of the inhibitory neurotransmitter GABA, blocks voltage‑gated sodium channels and modulates T‑type calcium currents. These actions collectively dampen neuronal hyper‑excitability, which is a key factor in seizures and related neurological disturbances.

The dose of Orfiril is individualized by the prescribing clinician based on the patient’s age, weight, clinical condition and response to therapy. Dosage adjustments are made during treatment to achieve optimal seizure control while minimising side effects.

Sodium valproate carries a known risk of birth defects and developmental disorders when used during pregnancy, so it is generally avoided in women of child‑bearing potential unless no safer alternative exists. Limited data are available for breastfeeding, and a risk‑benefit assessment should be performed by the prescriber.

To request Orfiril, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other anticonvulsants such as carbamazepine or lamotrigine, sodium valproate offers broad‑spectrum seizure control and mood‑stabilising properties but has a higher risk of liver toxicity and teratogenicity. Choice of therapy depends on the specific seizure type, comorbidities and individual patient risk factors.

Orfiril tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

Orfiril is supplied as oral tablets that are taken by mouth with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole and not chewed or crushed unless specifically advised.

Serious risks include severe liver injury, pancreatitis, hyperammonemic encephalopathy, thrombocytopenia and life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these conditions, and therapy should be stopped immediately if they occur.

Orfiril is contraindicated in individuals with known hypersensitivity to sodium valproate, those with severe liver disease, mitochondrial disorders such as POLG‑related disease, and pregnant women unless no alternative therapy is available. Clinicians must review each patient’s medical history before initiating treatment.